Compare Citius Pharmaceuticals Inc (CTXR) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs VNET Group Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while VNET Group Inc trades at $5.53 (market cap $1.47B). The key difference: VNET Group Inc is far larger — about 107.9× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 4,955,295). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and VNET Group Inc for 16 Days on average.
| CTXR | VNET | |
|---|---|---|
Market Cap | $13.62M | $1.47B |
Volume | 132,438 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $1.82 | $14.03 |
52-Week Low | $0.48 | $5.13 |
Typical Hold Time | 17 Days | 16 Days |
Enterprise Value | $3.79M | $5.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
VNET trades at $5.17, down 4.08% today, near 52-week lows. The stock is technically bearish with weak moving averages. Fundamentally, revenue grew to $9.95B in 2025, but net losses persist with a -22.18% margin. Recent news includes a strategic investment closing and a cooperation agreement with CATL.
Outlook remains challenged by losses and high leverage, though analyst consensus is moderately bullish. Key risks include negative cash flow and execution uncertainty. The stock offers speculative appeal if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
